Production and Use of Gesicles for Nucleic Acid Delivery
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Over-expression of the vesicular stomatitis virus glycoprotein (VSVG) in mammalian cells can induce the formation of VSVG-pseudotyped vesicles (named "gesicles") from membrane budding. Its use as a nucleic acid delivery tool is still poorly documented. Naked-plasmid DNA can be delivered in animal cells with gesicles in presence of hexadimethrine bromide (polybrene). However, little is known about gesicle manufacturing process and conditions to obtain successful nucleic acid delivery. In this study, gesicles production process using polyethylenimine (PEI)-transfected HEK293 cells was developed by defining the VSVG-plasmid concentration, the DNA:PEI mass ratio, and the time of gesicle harvest. Furthermore, parameters described in the literature relevant for nucleic acid delivery such as (i) component concentrations in assembly mixture, (ii) component addition order, (iii) incubation time, and (iv) polybrene concentration were tested by assessing the transfection capacity of the gesicles complexed with a green fluorescent protein (GFP)-coding plasmid. Interestingly, freezing/thawing cycles and storage at + 4 °C, - 20 °C, and - 80 °C did not reduce gesicles' ability to transfer plasmid DNA. Transfection efficiency of 55% and 22% was obtained for HeLa cells and for hard-to-transfect cells such as human myoblasts, respectively. For the first time, gesicles were used for delivery of a large plasmid (18-kb) with 42% of efficiency and for enhanced green fluorescent protein (eGFP) gene silencing with siRNA (up to 60%). In conclusion, gesicles represent attractive bioreagents with great potential to deliver nucleic acids in mammalian cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Molecular biotechnology - 64(2022), 3 vom: 01. März, Seite 278-292 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mangion, Mathias [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.03.2022 Date Revised 28.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12033-021-00389-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331382822 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331382822 | ||
| 003 | DE-627 | ||
| 005 | 20231225213334.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12033-021-00389-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331382822 | ||
| 035 | |a (NLM)34596870 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mangion, Mathias |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Production and Use of Gesicles for Nucleic Acid Delivery |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2022 | ||
| 500 | |a Date Revised 28.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Over-expression of the vesicular stomatitis virus glycoprotein (VSVG) in mammalian cells can induce the formation of VSVG-pseudotyped vesicles (named "gesicles") from membrane budding. Its use as a nucleic acid delivery tool is still poorly documented. Naked-plasmid DNA can be delivered in animal cells with gesicles in presence of hexadimethrine bromide (polybrene). However, little is known about gesicle manufacturing process and conditions to obtain successful nucleic acid delivery. In this study, gesicles production process using polyethylenimine (PEI)-transfected HEK293 cells was developed by defining the VSVG-plasmid concentration, the DNA:PEI mass ratio, and the time of gesicle harvest. Furthermore, parameters described in the literature relevant for nucleic acid delivery such as (i) component concentrations in assembly mixture, (ii) component addition order, (iii) incubation time, and (iv) polybrene concentration were tested by assessing the transfection capacity of the gesicles complexed with a green fluorescent protein (GFP)-coding plasmid. Interestingly, freezing/thawing cycles and storage at + 4 °C, - 20 °C, and - 80 °C did not reduce gesicles' ability to transfer plasmid DNA. Transfection efficiency of 55% and 22% was obtained for HeLa cells and for hard-to-transfect cells such as human myoblasts, respectively. For the first time, gesicles were used for delivery of a large plasmid (18-kb) with 42% of efficiency and for enhanced green fluorescent protein (eGFP) gene silencing with siRNA (up to 60%). In conclusion, gesicles represent attractive bioreagents with great potential to deliver nucleic acids in mammalian cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cell transfection conditions using gesicles | |
| 650 | 4 | |a Gene silencing | |
| 650 | 4 | |a Gesicles | |
| 650 | 4 | |a Gesicles production process | |
| 650 | 4 | |a Gesicles stability | |
| 650 | 4 | |a Hard-to-transfect cells | |
| 650 | 4 | |a Large plasmid delivery | |
| 650 | 4 | |a VSVG particles | |
| 650 | 7 | |a G protein, vesicular stomatitis virus |2 NLM | |
| 650 | 7 | |a Membrane Glycoproteins |2 NLM | |
| 650 | 7 | |a Nucleic Acids |2 NLM | |
| 650 | 7 | |a Viral Envelope Proteins |2 NLM | |
| 650 | 7 | |a enhanced green fluorescent protein |2 NLM | |
| 650 | 7 | |a Green Fluorescent Proteins |2 NLM | |
| 650 | 7 | |a 147336-22-9 |2 NLM | |
| 650 | 7 | |a Hexadimethrine Bromide |2 NLM | |
| 650 | 7 | |a 4C905MSK4W |2 NLM | |
| 700 | 1 | |a Robert, Marc-André |e verfasserin |4 aut | |
| 700 | 1 | |a Slivac, Igor |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert, Rénald |e verfasserin |4 aut | |
| 700 | 1 | |a Gaillet, Bruno |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular biotechnology |d 1994 |g 64(2022), 3 vom: 01. März, Seite 278-292 |w (DE-627)NLM075082349 |x 1559-0305 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2022 |g number:3 |g day:01 |g month:03 |g pages:278-292 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12033-021-00389-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2022 |e 3 |b 01 |c 03 |h 278-292 | ||